Integrated Investment Consultants’s AbbVie ABBV Stock Holding History

Integrated Investment Consultants’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.52M	Sell	14,008 -187	-1%	-$40.2K	0.69%	32
2026 Q1	$3.09M	Sell	14,195 -57	-0.4%	-$12.6K	0.66%	31
2025 Q4	$3.26M	Buy	14,252 +2,967	+26%	+$676K	0.64%	31
2025 Q3	$2.61M	Sell	11,285 -43	-0.4%	-$8.76K	0.44%	39
2025 Q2	$2.1M	Sell	11,328 -5,401	-32%	-$1M	0.41%	42
2025 Q1	$3.51M	Buy	16,729 +560	+3%	+$109K	0.7%	31
2024 Q4	$2.87M	Sell	16,169 -153,020	-90%	-$28.1M	0.59%	33
2024 Q3	$1.67M	Buy	169,189 +162,251	+2,339%	+$30.3M	0.36%	42
2024 Q2	$1.26M	Hold	6,938	–	–	0.35%	45
2024 Q1	$1.26M	Buy	6,938 +19	+0.3%	+$3.27K	0.35%	45
2023 Q4	$1.07M	Buy	6,919 +9	+0.1%	+$1.31K	0.34%	46
2023 Q3	$1.03M	Sell	6,910 -367	-5%	-$53.9K	0.37%	41
2023 Q2	$980K	Sell	7,277 -749	-9%	-$110K	0.31%	45
2023 Q1	$1.28M	Sell	8,026 -200	-2%	-$30.6K	0.4%	37
2022 Q4	$1.33M	Buy	8,226 +332	+4%	+$50.9K	0.45%	36
2022 Q3	$1.06M	Sell	7,894 -388	-5%	-$55.7K	0.42%	34
2022 Q2	$1.27M	Sell	8,282 -676	-8%	-$103K	0.46%	36
2022 Q1	$1.45M	Sell	8,958 -609	-6%	-$88.5K	0.39%	38
2021 Q4	$1.29M	Sell	9,567 -1,149	-11%	-$136K	0.35%	45
2021 Q3	$1.16M	Buy	10,716 +35	+0.3%	+$4K	0.34%	47
2021 Q2	$1.2M	Buy	10,681 +1,132	+12%	+$127K	0.35%	43
2021 Q1	$1.03M	Sell	9,549 -498	-5%	-$53.3K	0.36%	46
2020 Q4	$1.08M	Buy	10,047 +527	+6%	+$50.6K	0.41%	45
2020 Q3	$834K	Sell	9,520 -314	-3%	-$29.6K	0.39%	42
2020 Q2	$966K	Buy	9,834 +109	+1%	+$9.6K	0.46%	40
2020 Q1	$741K	Sell	9,725 -662	-6%	-$56.4K	0.44%	44
2019 Q4	$920K	Sell	10,387 -145	-1%	-$12K	0.38%	51
2019 Q3	$797K	Sell	10,532 -200	-2%	-$13.7K	0.41%	48
2019 Q2	$780K	Sell	10,732 -1,848	-15%	-$145K	0.4%	49
2019 Q1	$1.01M	Sell	12,580 -82	-0.6%	-$6.71K	0.54%	37
2018 Q4	$1.17M	Buy	12,662 +131	+1%	+$11.5K	0.63%	28
2018 Q3	$1.19M	Hold	12,531	–	–	0.58%	31
2018 Q2	$1.16M	Sell	12,531 -203	-2%	-$19.8K	0.61%	29
2018 Q1	$1.21M	Buy	+12,734	New	+$1.4M	0.48%	31
2017 Q3	$1.14M	Buy	12,799 +21	+0.2%	+$1.6K	0.49%	35
2017 Q2	$927K	Hold	12,778	–	–	0.42%	37
2017 Q1	$833K	Buy	12,778 +44	+0.3%	+$2.77K	0.38%	43
2016 Q4	$797K	Hold	12,734	–	–	0.38%	44
2016 Q3	$779K	Hold	12,734	–	–	0.4%	40
2016 Q2	$788K	Buy	12,734 +2,612	+26%	+$159K	0.45%	40
2016 Q1	$592K	Buy	10,122 +10	+0.1%	+$557	0.34%	51
2015 Q4	$595K	Buy	+10,112	New	+$582K	0.47%	43

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Integrated Investment Consultants's ABBV Position: Q2 2026 in Review

Integrated Investment Consultants reduced its AbbVie (ABBV) stake by 1.3% in Q2 2026, selling an estimated $40.2K and leaving 14,008 shares worth $3.52M. The position accounts for 0.69% of the portfolio, ranked #32.

Integrated Investment Consultants first reported a position in ABBV in Q4 2015 and has held it in 42 quarters since. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Integrated Investment Consultants held 14,008 shares of AbbVie worth $3.52M as of Q2 2026.
Integrated Investment Consultants sold 187 AbbVie shares in Q2 2026, an estimated $40.2K.
AbbVie made up 0.69% of Integrated Investment Consultants's portfolio in Q2 2026, its #32 holding.
Integrated Investment Consultants first reported a position in AbbVie in Q4 2015 and has held it in 42 quarters since.
4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Integrated Investment Consultants's 13F filing for Q2 2026, filed 17 Aug 2026.